Member Info for Soupdragon78

https://www.youtube.com/watch?v=0Gpm_miNC_A&t=17s

Quite clear that the base work on NXP002 is very successful, also missed by many is the point that they have data that could also see its value added in other indications.

Durability results January for completion of feasibility package which will be used for business development.

January.
Inhaler feasibility package completed.
Business development manger to be appointed.
Commence licence / partnering talks for NXP002
Commence talks to licence / sale of NXP004

Thats the plan.

Just a bit more Lanstead background for those who were whining on about IMM. Its obvious they are scaremongering to push people out as every example they have given has been proven to be the opposite of what they claimed.

IMM had a placing with Lanstead in Feb 2016 (when the sp was mid 20p's) which ran through to 4th Oct 2017 with the sp in the mid 50p's.

Below proves it was a good deal for IMM as the subscription was £4.4m but overall they received £5m.

"As announced on 5 February 2016, Lanstead subscribed for £4.4 million of new ordinary shares in ImmuPharma, with both parties also entering into the Sharing Agreement. All 18 settlements of the Sharing Agreement have now been completed. Through both the subscription and Sharing Agreement, ImmuPharma has received a total of just over £5.0 million from Lanstead, with a net gain of £0.6 million more than originally subscribed."

Also remember the recent interview where AR says that the Business Development Director will be 'initiating licensing discussions over the next few months'

"A partnering or licensing deal for NXP002 could be based on the new preclinical data set available fully from H1CY22. However, higher value will be achieved either when Phase 1 ready (from mid-2023), or with Phase 1 clinical safety and PK data (in H1 CY2024.)"

There is plenty of scope for something to happen over the next few months. Personally I think it may be some form of partnering set up being established to guide the next steps.

Agree OBW, anybody considering doing such a deal has to be sure they have something to help to sp otherwise is pointless getting less than you wanted.
They avoided debt because understandably as a R&D company they aren't revenue based, and they couldn't do a placing without a prospectus which would require sensitive info around NXP004 to be in the public domain.

Understand the frustration FX, but in all honesty as I've said before if AB hadn't been involved then we would not have seen any inhaler feasibility being done.
Pharma is a long game and not always a certain one.

Bought more the other day at 1.195p.

Currently sat on 2.94m shares at an average a fraction under 3p

Whilst it’s frustrating that the Allenby note doesn’t cover NXP004 other than saying it could provide unquantified upside. It’s entirely the right position for NFX to keep it close to its chest and not risk any commercial sensitivity.

I get the feeling the board took the view on the subscription with NXP004 in mind over the next few months.

Johnny, that’s why they stopped saying it would be a ‘significant payment’
We’ll have to see what the milestones are, but it’s clear the company aren’t bothered by it.

That would be at their risk FX.
I.e They sell 5m on day 1 at 1.15p netting £57,500.

Say the pricing day is day 30, with the price an average of the previous 20 days of say 1.3p. That would mean the reimburse NFX to the tune of £65,000, leaving them £7,500 down.

I would expect them to only sell once they know what they have to pay to NFX which will be late Jan. onwards.

FX, tranche 1 is effectively end of January as it’s determined by the 20 day average sp. that ties in with the stated 4 months for first phase through to end of April.

As I said, Allenby doesn’t take into account anything other than NXP002 and has adjusted for the increased shares.

Good price to be able to do that Moggy.

Thats for a phase 1 ready valuation, the recent notes have reiterated a fair current valuation as it stands now.

Still looking at current fair value up to 2.8p at the moment.

I feel news on a Business Development Director will help that. Also the report doesn't cover any of NXP004 which I feel the company is banking on to drive the sp on the near term.

https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2021/12/20211216-Allenby-Capital-Nuformix-plc-NFX.L-Interims-update-and-funding.pdf?c2649=on

They're non-exec so I'm not that concerned by their holding.

Fair value as of July was 1.7p to 3.4p prior to news on NXP001, NXP002 success and NXP004 success.

Go figure.

Key appointment will be the business development director, it’s clear that they have a strategy lined up which will see them develop alongside a major with a view to licensing once phase 1 ready.

Also will be interesting to see Allenby’s view now. They typically take a few days after announcement to piece together their report.

Yeah not happy with that. They seem determined to trash British companies for their profit.